Retatrutide is an investigational injectable therapy developed by Eli Lilly & Co. to explore new ways of addressing obesity and metabolic imbalance.
Unlike earlier medications that influence one or two hormone pathways, Retatrutide activates three — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptors — to regulate appetite, energy expenditure and fat metabolism.
This triple-agonist approach is currently being studied for its potential to deliver broader metabolic outcomes compared with established GLP-1 and dual-agonist options such as Ozempic (Semaglutide) and Mounjaro (Tirzepatide).
In a Phase 2 trial published in The New England Journal of Medicine, participants using Retatrutide achieved an average weight reduction of roughly 24 percent over 48 weeks — a significant result observed in early-stage research.
The treatment has attracted international media attention. Dazed Digital and Business Insider have referred to Retatrutide as the “Godzilla of weight loss injections,” reflecting growing public curiosity about this next-generation compound. Despite the nickname, Retatrutide remains in clinical testing and is not approved for medical use.
Phase 3 studies are in progress to determine its long-term safety and efficacy. Although not yet available in Singapore, Retatrutide may become a future addition to doctor-supervised weight management once regulatory review is complete.
Retatrutide is a triple-agonist weight loss injection designed to target obesity and related metabolic conditions through multiple hormonal pathways.
It acts on GLP-1, GIP and glucagon receptors to assist in appetite control, glucose regulation and fat breakdown while helping preserve lean muscle mass. Clinical programmes are evaluating its efficacy, tolerability and long-term metabolic effects across diverse populations.
Retatrutide’s three-hormone targeting mechanism is intended to address multiple aspects of metabolism.
By integrating these pathways, Retatrutide aims to produce sustained weight reduction with balanced metabolic adaptation. Ongoing research will clarify how this triple-agonist design influences body composition and long-term results.
Following the success of earlier GLP-1 and dual-agonist agents, Eli Lilly developed Retatrutide as part of its metabolic research pipeline. Preclinical data suggested that activating three hormone receptors could enhance appetite control and energy use.
Subsequent human studies were launched in individuals with obesity and type 2 diabetes to verify these findings. The results of Phase 3 trials will determine its future clinical role once regulatory approval is pursued.
Phase 2 research has shown encouraging outcomes, with participants achieving average weight reductions of around 24 percent over 48 weeks. Improvement was also observed in fasting glucose, lipid profiles and blood pressure.
The most common side effects were transient gastrointestinal symptoms such as nausea and diarrhoea, which typically lessened as treatment continued. Large-scale Phase 3 studies are now under way to confirm these findings across broader populations.
Retatrutide is not yet available for prescription in Singapore or other markets. The medication is still under clinical evaluation and has not been approved by the U.S. FDA or Singapore’s Health Sciences Authority (HSA). Based on current timelines, approval and local availability are expected after 2026.
For patients interested in safe, approved options, doctor-prescribed GLP-1 therapies such as Ozempic (Semaglutide), Wegovy (Semaglutide 2.4 mg), Mounjaro (Tirzepatide), and Rybelsus (Oral Semaglutide) are currently available in Singapore under medical supervision. Unverified or grey-market versions should be avoided for safety reasons.
Over the past decade, incretin-based treatments like semaglutide and tirzepatide have transformed the medical approach to obesity management. These medications act on GLP-1 or combined GLP-1/GIP receptors to help reduce appetite and improve metabolic health. Retatrutide builds upon this foundation by introducing additional glucagon receptor activity, which is under study for its potential to further enhance energy use and fat metabolism.
While existing treatments such as Ozempic, Wegovy, and Mounjaro are approved for use in Singapore, Retatrutide is still under investigation. Its development marks an important continuation of scientific efforts to refine and personalise future weight management therapies.
In Singapore, several clinically approved treatments are available under doctor guidance to help manage weight safely and effectively. They include:
These therapies are prescribed within structured programmes that include medical assessment, dose adjustment and ongoing review to ensure safety and effectiveness. Patients can book a consultation with Dr Edwin Lim at Edwin Lim Medical Aesthetic Clinic to learn more:
https://botoxsingapore.sg/contact-us/.
Is Retatrutide Available in Singapore?
No. Retatrutide is still under clinical evaluation and awaiting regulatory approval. Availability is expected after 2026 pending successful trial outcomes.
How Much Weight Loss Has Been Reported?
Phase 2 data showed average weight reductions of up to 24 percent over 48 weeks in participants with obesity or overweight.
How Does Retatrutide Work?
It stimulates GLP-1, GIP and glucagon receptors to help control appetite, improve insulin sensitivity and increase energy expenditure.
What Are the Common Side Effects?
Most reported effects are gastrointestinal (nausea, vomiting, diarrhoea) and tend to resolve as treatment continues. Long-term safety data are pending.
When Could It Be Launched?
Pending Phase 3 completion and regulatory review, launch may occur in 2026 or later.
Which Weight Loss Medications Are Currently Approved in Singapore?
Ozempic (Semaglutide) | Wegovy (Semaglutide 2.4 mg) | Mounjaro (Tirzepatide) | Rybelsus (Oral Semaglutide)
Can Patients Pre-Register for Retatrutide?
No pre-registration is available because the drug is still in the research phase. Patients can consult their doctor for updates and review current approved options instead.
Copyrights 2025 by Edwin Lim Medical Aesthetic Clinic Pte. Ltd.
